Immunoglobulin therapy represents a lifesaving intervention for many
patients with primary immunodeficiency (PID). Antibody defects represent approximately
half of the well-known PIDs requiring immunoglobulin replacement therapy. Following
immunoglobulin therapy in PID patients, protection against serious upper and lower
respiratory tract infections and pulmonary function improves which leads to an
increase in the quality of life of these patients. Successful treatment of PID patients
depends on the type of immunodeficiency, regular monitoring of the patient, comorbidities
of the patient, and the availability of the products.